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ORIGINAL ARTICLE
Hypothesis: This study explored whether chemotherapy after first-
line gefitinib was effective in patients with advanced lepidic predom-
inant adenocarcinoma (LPA), formerly advanced bronchioloalveolar 
carcinoma, who were enrolled in the Intergroupe Francophone de 
Cancérologie Thoracique (IFCT)-0401 trial.
Methods: Overall, 88 patients presenting advanced LPA were 
enrolled in the IFCT-0401 trial, receiving gefitinib as first-line ther-
apy. No predefined second-line treatment was mandatory in the case 
of progression or limiting toxicity under gefitinib. However, the car-
boplatin plus paclitaxel regimen was recommended for patients with 
a performance status (PS) 0 or 1 and gemcitabine monotherapy for 
those with a PS 2. For these patients, data concerning treatment effi-
cacy was collected from the IFCT-0401 trial database.
Results: In total, 47 patients (53%) received second-line treatment 
after the failure of gefitinib, with 43 having PS 0 or 1. Regarding 
treatment, 43 were treated with chemotherapy, with 38 receiving a 
platinum-doublet regimen (taxane-based, n = 29; gemcitabine-based, 
n = 9) and five receiving monotherapy (gemcitabine, n = 3; peme-
trexed, n = 2). The overall response rate (ORR) to chemotherapy was 
21% (95% confidence interval [CI]: 10–36), disease control rate 56% 
(95% CI: 40–71), and median progression-free survival (PFS) 3.0 
months (95% CI: 2.4–4.9). For patients receiving a platinum dou-
blet (n = 38), ORR was 21% (95% CI: 10–37), with disease con-
trol rate being 55% (95% CI: 38–71), and median PFS 2.9 months 
(95% CI: 2.4–4.4). For patients receiving taxane-based regimen 
(n = 29) and gemcitabine-based regimen (n = 12), ORR was 28% 
and 0%, respectively, with a median PFS of 3.3 and 2.0 months, 
respectively, (p = 0.0243). The two patients receiving pemetrexed 
experienced a prolonged response. Multivariate Cox model analysis 
revealed that only the use of taxane-based chemotherapy or peme-
trexed was related to PFS.
Conclusion: Platinum-doublet chemotherapy showed some effec-
tiveness in treating advanced LPA patients after first-line gefitinib. 
Our findings also suggest that taxane-based chemotherapy and 
pemetrexed should be investigated further in future clinical trials.
Key Words: Non–small-cell lung cancer, Lung adenocarcinoma, 
Bronchioloalveolar carcinoma,  Paclitaxel,  Pemetrexed.
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Bronchioloalveolar carcinoma (BAC) is a rare histologi-cal subtype of lung adenocarcinoma (ADC), accounting 
for 3% to 4% of all non–small-cell lung cancers (NSCLC). 
The disease is defined in the 2004 revised classification of 
the World Health Organization (WHO) and International 
Association for the Study of Lung Cancer (IASLC) as an 
ADC proliferation arising from acinar and bronchiolar cells 
with no evidence of stromal, pleural, or vascular invasion.1 
Diagnosis can only be established after pathological tumor 
analysis excludes evidence of a histological invasion after 
complete surgical resection. This strict definition was sub-
stantiated by the 100% 5-year survival rate of less than 3 cm 
peripheral ADC, with pure BAC now termed adenocarcinoma 
in situ.2 Former ADC with BAC features, being more frequent, 
has recently been termed invasive nonmucinous (NM) lepidic 
predominant ADC (LPA) along with its mucinous variant, as it 
displays several foci of invasion, but with predominant lepidic 
features.3 Given the “lepidic” growth pattern and aerogenous 
propagation of these tumors, ipsilateral, and contralateral pul-
monary recurrences, but with uncommon extrapulmonary 
metastases,4 are frequently observed. This cancer type shares 
similar characteristics with adenocarcinoma in situ in terms of 
epidemiology (no gender bias; nonsmokers or mild smokers), 
clinical and radiological findings (better performance status 
[PS], less advanced diagnostic stage, ground-glass or alveolar 
pattern on computed tomography [CT] scan), and prognosis 
(more indolent course and better prognosis compared with 
other ADC subtypes).5
Historically, advanced LPA, formerly advanced BAC, 
was widely perceived as being chemoresistant, with older 
retrospective studies reporting conflicting results.6–11 In the 
prospective Eastern Cooperative Oncology Group (ECOG) 
1594 trial comparing four platinum-based chemotherapy regi-
mens as first-line therapy in advanced NSCLC patients, LPA 
response rates to chemotherapy were lower than other NSCLC 
pathological subtypes (6% versus 20%).6 As advanced LPA 
patients are frequently excluded from NSCLC trials, little is 
known about optimal treatment, thus justifying the initiation 
of specific trials.12 There are only two nonrandomized phase 
II trials specifically focused on advanced LPA, studying the 
effectiveness of paclitaxel monotherapy.13,14 However, the low 
response rates along with unacceptable toxicity observed in 
the Southwest Oncology Group (SWOG) 9714 trial using a 
96-hour infusion regimen did not support the use of such a 
chemotherapeutic approach.13 In addition, three phase II trials 
evaluated the use of epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR-TKI) as first-line or second-
line treatment for patients with advanced LPA. Encouraging 
results involving control rates of 29% to 58% and overall 
survival of 13 to 17 months along with a favorable toxicity 
profile lent support to the EGFR-TKI approach (Table 1).15–17  
Recently, similar results were reported using anti-EGFR 
antibody monotherapy as first-line or second-line therapy in 
advanced LPA patients.18
Pathological classification distinguishes three histo-
logical subtypes: NM, mucinous (M), and mixed. This histo-
logical classification appears to be clinically relevant in terms 
of treatment efficacy, likely due to the distinctive molecular 
tumor profile.19,20 NM tumors often exhibit EGFR mutations, 
with M tumors frequently presenting K-Ras mutations.21–23 
Importantly, the presence of the EGFR mutation is predictive of 
EGFR-TKI response, whereas the K-Ras mutation appears to 
be associated with EGFR-TKI resistance.16,24 The Intergroupe 
Francophone de Cancérologie Thoracique (IFCT)-0401 trial 
showed that patients with NM tumors displayed significantly 
improved progression-free survival (PFS) with gefitinib, 
whereas patients with M tumors did not,17 which is in line with 
the differing molecular profiles of these two histological sub-
types.24 Overall survival curves, however, did not diverge until 
22 months, suggesting that chemotherapy given after gefitinib 
was effective in patients with M tumors as “salvage” therapy. 
Furthermore, radiological response to the 96-hour infusion 
of paclitaxel in the SWOG 9714 trial was observed in the M 
tumors (3 of 16) and not in the NM tumors (0 of 13).13
The aim of this study was to describe the characteris-
tics of patients with advanced LPA who received a second- or 
third-line treatment after the failure of gefitinib as part of the 
IFCT-0401 trial. Furthermore, we explored the effectiveness 
of the different therapeutic regimens administered, with a spe-
cial focus on chemotherapy.
MATERIALS AND METHODS
Summary of the IFCT-0401 Trial
The prospective multicentre phase II IFCT-0401 trial 
was conducted between April 2004 and July 2005 to evalu-
ate gefitinib 250 mg daily as front-line therapy in treatment-
naive patients with nonresectable advanced LPA, formerly 
advanced BAC.17 Disease control rate (DCR) was the primary 
endpoint. Eligibility criteria were the following: histologically 
or cytologically proven advanced LPA from the outset or after 
recurrence; PS of 0, 1, 2, or 3; one or more pulmonary lesions 
evaluable on CT scan; fiberoptic bronchoscopy with macro-
scopically normal findings. A chest radiograph and CT scan 
of the chest, brain, and upper abdomen were performed before 
inclusion. Response rates and disease control were assessed 
with the same imaging methods employed for the baseline 
TABLE 1. Results of Phase II Trials in Advanced Lepidic 
Predominant Adenocarcinoma, Formerly Advanced 
Bronchioloalveolar Carcinoma, in the First-Line and Second-
Line Setting
Trial No.
ORR 
(%)
DCR 
(%)
PFS in  
months  
(median)
OS in  
months  
(median)
EORTC 0895614; paclitaxel 19 11* 54 2 9
SWOG 971413; paclitaxel 58 14 — 5 12*
Miller16; erlotinib 75 22* 60 4 17
SO12615; gefitinib 136 17 49 3.6 13.0*
IFCT-040117; gefitinib 88 13 30* 2.9 13.2
ECOG-150418; cetuximab 68 7* 42 3.3 13.0
*Trial primary endpoints
DCR, disease control rate; PFS, progression-free survival; OS, overall survival; 
EORTC, European Organisation for Research and Treatment of Cancer; SWOG, 
Southwest Oncology Group; IFCT, Intergroupe Francophone de Cancérologie 
Thoracique; ECOG, Eastern Cooperative Oncology Group.
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tumor assessment and using the WHO criteria.17 In total, 88 
patients were enrolled, with none lost to follow-up. Written 
informed consent was obtained after providing comprehen-
sive information about the investigational nature of the proto-
col. The protocol was approved by the local ethics committees 
and regulatory authorities.
Chemotherapy Effectiveness in Advanced LPA
Describing the effect of second-line and third-line 
chemotherapy was a secondary objective of the IFCT-
0401 trial. No predefined second-line chemotherapy was 
mandatory in the case of progression or limiting toxicity under 
gefitinib. However, a carboplatin plus paclitaxel regimen was 
recommended for patients with PS 0 or 1 and gemcitabine 
monotherapy for those with PS 2.
Data taken from patients receiving second-and third-
line treatment after the failure of gefitinib was collected 
from the IFCT-0401 trial database. The following data were 
collected for each line of treatment: PS at treatment initia-
tion, date of first infusion, drugs used according to eight 
categories (cisplatin, carboplatin, paclitaxel, docetaxel, gem-
citabine, vinorelbine, pemetrexed, and other), number of 
cycles, best response according to five categories (complete 
response, partial response, stable disease, progression, and 
nonevaluable), grade 3 and 4 treatment toxicity, and date and 
reason for treatment failure (progression, toxicity, death, and 
other).
Patients were followed up using clinical and CT evalu-
ations every 3 months until death. Response was evaluated 
by CT scan and assessed by investigators according to the 
WHO criteria, as defined in the original IFCT-0401 protocol.17 
Disease control was defined as no radiological or clinical pro-
gression at the time of best response after a minimum of 6 
weeks of treatment.
EGFR and K-Ras Mutation Analysis
Overall, 62 formalin-fixed and paraffin-embedded 
tumor samples were collected from the 88 patients enrolled in 
the IFCT-0401 trial, with 34 obtained by surgical exeresis and 
28 either by CT-directed core needle biopsy or transbronchial 
biopsy. Briefly, for each sample, a 3-µm tissue section was 
stained with hematoxylin and eosin and examined by light 
microscopy to determine the presence of tumor cells. After 
DNA isolation (QIAamp DNA mini kit; Qiagen, Courtaboeuf, 
France) from three 20-µm tissue sections, EGFR 18–21 and 
K-Ras 2 exons were amplified and sequenced in both direc-
tions and analyzed using the SeqScape software, as previously 
described.24
Statistical Analysis
All eligible patients from the IFCT-0401 trial were 
enrolled. Characteristics of patients who did or did not receive 
second-line therapy were compared using the χ2 or Fisher’s 
exact test. Comparisons were also performed according to 
therapeutic regimens for patients receiving chemotherapy.
An analysis of efficacy was performed on the overall 
study population. Overall response rates (ORR) and DCR 
were given with their 95% exact confidence intervals (CI) 
and compared using Fisher’s exact test. PFS was defined as 
the time from treatment initiation to disease progression diag-
nosed by CT scan or to all-cause death, and was assessed using 
the Kaplan–Meier method. Cox univariate analysis was under-
taken to identify the covariables associated with the risk of 
progression or death in the second-line setting. The following 
variables were analyzed: sex (men versus women), age (≤70 
years versus >70 years), PS (0–1 versus 2–3), smoking status 
(smoker versus nonsmoker), stage at diagnosis (I–IIIA versus 
IIIB–IV), respiratory symptoms score (<9 versus ≥9), DCR at 
3 months using gefitinib (control versus noncontrol), EGFR 
and K-Ras mutational status (mutated versus wild type), and 
second-line treatment (pemetrexed versus taxane-based ver-
sus gemcitabine-based chemotherapy). Variables with p value 
less than 0.2 were included in a multivariate Cox’s regression 
model and selected using a backward procedure. Two-sided 
p values of less than 0.05 were considered to indicate statisti-
cal significance.
RESULTS
Characteristics of Patients Receiving Second-
Line Treatment
In total, 47 of the 88 (53%) patients enrolled in 
the IFCT-0401 trial received second-line treatment after 
gefitinib failure. Table 2 compares the clinical and molecular 
characteristics of patients who did (n = 47) and did not 
receive second-line therapy (n = 41). Patients eligible for 
second-line treatment had a lower DCR at 3 months with the 
initial gefitinib therapy (p = 0.005). They were also younger 
(p = 0.007) and had a better PS (p = 0.01) at the IFCT-0401 
trial inclusion. The frequency of EGFR and K-Ras mutations 
did not differ between the two groups.
Description of Treatment and Related Toxicity
Details of the drugs administrated as second- and 
third-line treatment and related toxicities are provided in 
Table 3. Dose and schedule regimens are presented in the 
Supplementary Tables (Supplemental Digital Content 1 and 2, 
http://links.lww.com/JTO/A315 and http://links.lww.com/
JTO/A316). Regarding treatment, 43 patients were treated 
with chemotherapy as second-line treatment, with 38 receiv-
ing a platinum-doublet regimen (taxane-based, n = 29; 
gemcitabine-based, n = 9) and five receiving monotherapy 
(gemcitabine, n = 3; pemetrexed, n = 2). The clinical charac-
teristics and EGFR and K-Ras mutational status of patients 
receiving taxane-based or gemcitabine-based chemotherapy 
were not different (Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A315). The 
remaining four patients received a targeted therapy (bort-
ezomib, n = 3; erlotinib, n = 1). Three cases of grade 3 or 
4 toxicity resulted in treatment discontinuation. Two patients 
experienced a grade 3 sensory neuropathy under a taxane-
based regimen, while one patient had a grade 4 febrile neu-
tropenia under a gemcitabine-based regimen. In addition, 
11 patients received pemetrexed monotherapy as second- line 
treatment (n = 2) or third-line treatment (n = 9), without any 
grade 3 or 4 limiting toxicity.
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Effectiveness of Second-Line and Third-Line 
Treatment
In the second-line setting, ORR with chemotherapy 
was 21% (9 of 43) (95% CI: 10–36), DCR 56% (95% CI: 
40–71), and median PFS 3 months (95% CI: 2.4–4.9). For 
patients receiving a platinum doublet (n = 38), ORR was 21% 
(95% CI: 10–37), DCR 55% (95% CI: 38–71), and PFS 2.9 
months (95% CI: 2.4-4.4). Data for the ORR, DCR, and PFS 
after second- line therapy and third-line therapy with taxane- 
based chemotherapy and gemcitabine-based chemotherapy or 
pemetrexed monotherapy is provided in Table 4.
Univariate analysis revealed that achieving higher 
DCR at 3 months with gefitinib (p = 0.04) and using taxane-
based chemotherapy (p = 0.02) or pemetrexed (p = 0.02) as 
second-line treatment were favorable prognostic factors for 
PFS (Table 5). Multivariate analysis confirmed that the type 
of second-line treatment was an independent prognostic 
factor. Kaplan–Meier curves for PFS according to the use of 
taxane- and gemcitabine-based chemotherapy are illustrated 
in Figure 1. A waterfall plot of PFS for each patient according 
to the third-generation drugs used for second- and third-line 
treatments is shown in Figure 2A, B, respectively. A waterfall 
plot of individual PFS values for each patient according to 
NM or M histological subtypes is illustrated in Figure 3. 
EGFR and K-Ras mutation status did not impact these results.
DISCUSSION
Little data is available concerning chemotherapy 
effectiveness in patients with advanced LPA. Only two 
noncontrolled phase II trials have examined this issue, 
with disappointing results obtained with the two different 
schedules of paclitaxel monotherapy. In the European 
Organisation for Research and Treatment of Cancer 
(EORTC) 08956 trial,14 200 mg/m2 of paclitaxel administered 
every 3 weeks was shown to be well tolerated, but with an 
ORR of 11%, leading to trial discontinuation. In the SWOG 
9714 trial, the observed 14% ORR and 5-month median 
PFS appeared encouraging,13 but the 96-hour infusion 
schedules of paclitaxel were highly toxic, resulting in six 
treatment-related deaths. Consequently, this treatment 
TABLE 3.  Description of Drugs Used as Second-Line and 
Third-Line Therapy After the Failure of Gefitinib and Related 
Grade 3 or 4 Toxicities 
Drugs Used
Second-Line Third-Line
n (%)
Grade 3/4 
Toxicity n (%)
Grade 3/4 
Toxicity
Taxane-based  
chemotherapy
29 (62%) 2 (7%) 6 (19%) 2 (33%)
Carboplatin-paclitaxel 24 2 2 0
Carboplatin-docetaxel 4 0 1 0
Cisplatin-docetaxel 1 0 0
Paclitaxel 0 2 2
Docetaxel 0 1 0
Gemcitabine-based  
chemotherapy
12 (26%) 1 (8%) 8 (26%) 3 (43%)
Carboplatin-gemcitabine 3 1 2 1
Cisplatin-gemcitabine 6 0 2 1
Gemcitabine 3 0 4 1
Pemetrexed 2 (4%) 0 9 (29%) 0
Others 4 (7%) 0 8 (26%) 0
Bortezomib 3 0 0
Erlotinib 1 0 7 0
RAD 001 0 1 0
TABLE 2. Clinical and Biological Characteristics of Patients 
Who Did and Did Not Receive Second-Line Treatment After 
the Failure of Gefitinib 
Characteristics
No. of 
2nd line 
treatments
2nd line 
treatment
p
n = 41 n = 47
n (%) n (%)
Sex
 Female 22 (54) 26 (55) 0.876
 Male 19 (46) 21 (45)
Age
 ≤70 years 20 (49) 36 (77) 0.0068
 >70 years 21 (51) 11 (23)
Performance status
 0–1 29 (71) 43 (91) 0.0118
 2–3 12 (29) 4 (8)
Smoking
 Smoker 24 (59) 26 (55) 0.7612
 Nonsmoker 17 (41) 21 (45)
Stage at diagnosis
 Stage I–IIIA 5 (12) 10 (21) 0.2584
 Stage IIIB–IV 36 (88) 37 (79)
Histological subtype
 Nonmucinous 10 (24) 11 (23) 0.9732
 Mucinous 18 (44) 20 (43)
 Unspecified 13 (32) 16 (34)
RSS
 ≤9 25 (61) 23 (49) 0.1913
 >9 14 (33) 23 (49)
 MD 2 (6) 1 (2)
EGFR status
 Mutated 4 (10) 3 (6) 0.6228
 Wild type 22 (54) 27 (57)
 NA 3 (7) 3 (6)
 MD 12 (29) 14 (31)
K-Ras status
 Mutated 5 (12) 4 (8) 0.4815
 Wild type 17 (41) 24 (50)
 NA 7 (17) 5 (11)
 MD 12 (30) 14 (31)
DCR at 3 mo with gefitinib
 No 21 (51) 39 (83) 0.0053
 Yes 17 (42) 8 (17)
 MD 3 (7) 0 (0)
p value investigated using χ2 test or Fisher’s exact test.RSS, respiratory symptoms 
score; MD, missing data; EGFR, epidermal growth factor receptor; NA, nonamplifiable; 
DCR, disease control rate.
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option should not be considered for routine use. There is no 
available data regarding the efficacy of platinum-based or 
other chemotherapeutic regimens in patients with advanced 
LPA after first-line EGFR TKI.
In the IFCT-0401 trial, 53% of patients were eligible 
for second-line therapy. Our results suggest that platinum-
based doublet regimens were well tolerated and effective after 
front-line gefitinib therapy in advanced LPA. In the second-line 
setting, platinum-based doublets were administrated to 38 out 
of 47 patients (81%) and had a good safety profile, with only 
three cases of treatment discontinuation observed due to grade 
3 or 4 toxicity (Table 3). Platinum-based doublets exhibited 
favorable efficacy results, with an ORR of 21%, DCR of 55 
%, and median PFS of 2.9 months (range, 0.7–17.1 months).
TABLE 4.  Progression-Free Survival, Overall Response Rate, and Disease Response Rate of Second-Line and Third-Line 
Therapies After Gefitinib Treatment According to the Chemotherapy Regimen
Line
Taxane-Based 
Chemotherapy
Gemcitabine-Based 
Chemotherapy Pemetrexed Total p
Second-Line n = 29 n = 12 n = 2 n = 43
 PFS, mo, (95% CI) 3.3 (2.6–5.7) 2.0 (1.4–2.7) 10 and 32 3.0 (2.4–4.9) 0.0072
 ORR, n, % (95% CI) 8, 28% (13–47) 0 1 (NA) 9, 21% (10–36) 0.0734
 DCR, n, % (95% CI) 18, 62% (44–80) 4, 33% (10–65) 2 (NA) 24, 56% (40–71) 0.1265
Third-line n = 6 n = 8 n = 9 n = 22
 PFS, mo, (95% CI) 3.4 (NA) 2.2 (NA) 5.7 (NA) 2.9 (2.4–4.9) <0.0001
 ORR, n, % (95% CI) 2 (NA) 1 (NA) 4 (NA) 7, 30% (13–53) 0.4490
 DCR, n, % (95% CI) 4 (NA) 3 (NA) 7 (NA) 14, 61% (39–80) 0.2749
PFS, progression-free survival; DCR, disease control rate; CI, confidence interval; NA, non applicable.
TABLE 5.  Univariate and Multivariate Analyses of Progression-Free Survival When Using Second-Line Chemotherapy
Variable No. of Patients
Univariate Hazard  
Ratio (95% CI) p
Multivariate Hazard 
Ratio (95% CI) p
Sex
 Male 18 0.52 (0.27–1.01) 0.0549
 Female 25 1
Age
 >70 yr 11 0.60 (0.29–1.23) 0.1662
 ≤70 yr 32 1
RSS
 <9 19 0.69 (0.37–1.29) 0.2440
 ≥9 23 1
Stage at diagnosis
 I–IIIA 7 1.00 (0.44–2.29) 0.9968
 IIIB–IV 36
DCR at 3 mo with gefitinib
 Yes 6 0.37 (0.14–0.95) 0.0382
 No 37 1
EGFR status
 Mutated 3 0.58 (0.17–1.98) 0.3879
 Wild type 24 1
K-Ras status
 Mutated 22 0.47 (0.13–1.67) 0.2409
 Wild Type 3 1
Performance status
 2 4 0.66 (0.23–1.86) 0.4267
 0–1 39 1
Treatment used in second line
 Pemetrexed 2 0.08 (0.01–0.63) 0.0165 0.08 (0.01–0.63) 0.0165
 Taxan-based chemotherapy 29 0.44 (0.21–0.90) 0.0249 0.44 (0.21–0.90) 0.0249
 Gemcitabine-based chemotherapy 12 1
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Taxane-based (paclitaxel n = 24 and docetaxel n = 5) 
and gemcitabine-based (n = 12) chemotherapy were the 
most common regimens used in the second-line setting. 
However, treatment efficacy appeared to be associated with 
the type of platinum-based doublet or monotherapy used. 
The ORR, DCR, and PFS were in favor of taxane- rather than 
gemcitabine-based chemotherapy (ORR 28% versus 0%, 
p = 0.04; DCR 62% versus 33%, p = 0.09; PFS 3.3 versus 
2.0 months, p = 0.02) (Table 4; Figs. 1 and 2). Second-line 
pemetrexed monotherapy was administered to two patients, 
demonstrating notable prolonged responses of 10 and 32 
months. In multivariate analyses, the use of taxane-based 
chemotherapy (n = 29) or pemetrexed (n = 2) was associated 
with a better PFS in the second-line setting. However, caution 
is needed when interpreting PFS, ORR, and DCR because of 
our retrospective study design and the absence of a central 
review of radiological responses. In addition, given the small 
number of patients, our study lacked statistical power.
The molecular rationale behind the lack of gemcitabine 
efficacy in advanced LPA patients is still unclear. Gemcitabine 
acts by blocking DNA strand elongation through inhibition 
of the intracellular ribonucleoside-diphosphate reductase 
large subunit target encoded by the RRM1 gene. High levels 
of RRM1 expression were proposed to be predictors of low 
response rates to gemcitabine in several NSCLC clinical 
studies.25,26 However, differential RRM1 expression types in 
various histological NSCLC subsets, especially in LPA, were 
never demonstrated. In contrast, in the IFCT-0401 population, 
second-line taxane-based chemotherapy was associated with 
promising ORR (28%) contrary to the ORR observed with 
first-line paclitaxel monotherapy in the EORTC 0895614 and 
SWOG 971413 trials (11% and 14%, respectively). High 
levels of βIII-tubulin isoform expression, which is targeted 
by tubulin-binding agents, such as taxanes, may be predictive 
of poor responses to taxane- and platinum-based agents in 
advanced NSCLC.26,27 As the βIII-tubulin isoform expression 
is unknown with regards to LPA, LPA sensitivity to taxane-
based regimens need to be further explored.
The efficacy profile of the multitargeted antifolate 
pemetrexed may be accounted for by the following rationale. 
Firstly, its efficacy profile tends to be better than that 
achieved with gemcitabine-based chemotherapy (Table 5; 
Fig. 2). Furthermore, pemetrexed efficacy appeared to be 
preserved when given as third-line therapy (Table 5; Fig. 2) 
or even fourth-line therapy (data not shown) in patients 
previously treated with EGFR-TKI and gemcitabine-based or 
taxane-based regimens. As previously reported,28 two patients 
experienced successive responses after resuming pemetrexed 
therapy. This observation suggests that a subset of tumors 
were highly sensitive to pemetrexed without developing 
secondary resistance after exposure to pemetrexed. However, 
the molecular determinants of its efficacy are still unknown.29 
In a large phase III trial comparing cisplatin/pemetrexed with 
cisplatin/gemcitabine combinations as front-line treatment of 
advanced NSCLC, a significant survival difference was shown 
in the histological ADC subgroup when using the cisplatin/
pemetrexed regimen.30 A lower expression of thymidilate 
synthase (TS) in ADC versus squamous cell carcinoma may 
explain this survival difference.31,32 Nevertheless, no data is 
available regarding TS expression in advanced LPA patients. 
In a preclinical trial, an overexpression of FR-α, a folate 
receptor with high affinity for pemetrexed, was suggested to 
be present in LPA tumors as compared with mesothelioma and 
non-LPA lung ADC.33 In a recent case report, Garfield et al. 
described a dramatic response to pemetrexed after the rapid 
failure of the carboplatin and paclitaxel regimen in a patient 
with a M histological subtype presenting FR-α overexpression 
(approximately 30% of tumor cells with 3+ intensity).34
In our study, NM and M histological subtypes were not 
found to be strong predictors of PFS (Fig. 3), response, or DCR 
after chemotherapy (Supplementary Table 2, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A316). When 
considering second- and third-line therapy, an objective 
response was observed in six of 14 NM tumors (43%) and 
eight of 29 M tumors (27%). The ORR was 31% (5 of 16) and 
DCR 56% (9 of 16) in patients with M tumors being treated 
with taxane-based regimens. As suggested in the SWOG 9714 
trial, taxanes proved effective in the M subtype. Finally, EGFR 
and K-Ras mutation status did not impact on chemotherapy 
efficacy.
The observation and hypothesis that taxane-based regi-
mens and pemetrexed allowed for disease control in cases of 
rapid EGFR-TKI failure were specifically addressed in the 
IFCT-0504 trial.35 In this trial, advanced LPA patients were 
randomly assigned to receive either erlotinib or carboplatin 
and weekly paclitaxel as front-line therapy, with a crossover 
treatment being administered at 1 month in the case of disease 
progression and pemetrexed being given as third-line treat-
ment after crossover treatment failure. Essential information 
is likely to arise from ongoing trials regarding the predic-
tive role of NM or M histological subtypes, EGFR and K-Ras 
mutational statuses, and biological factors, such as PAS-
diastase resistance staining, βIII-tubulin, expression of muta-
tor gene homologue 2, and TS by immunohistochemistry. 
FIGURE 1. Curve for progression-free survival using gem-
citabine-based chemotherapy (black line) or taxane-based 
chemotherapy (green line) as second-line treatment.  
CI, confidence interval.
1429Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, September 2012 Chemotherapy in Advanced LPA
SWOG 052636 was the first phase II trial to investigate peme-
trexed efficacy when given as first- or second-line therapy in 
advanced LPA patients, with an analysis of folate markers 
(TS, FR-α) and EGFR and K-Ras mutational status in both 
tumor specimens and blood samples. The results are still 
pending.
A
B
FIGURE 2.  Waterfall plot of progression-free survival in second-line therapy (A) and third-line therapy (B) for each patient 
according to the third-generation chemotherapy regimens used. Median progression-free survival in months and its extent 
according to each third-generation chemotherapy regimen is shown in the insert box. Patients who discontinued treatment 
because of toxicity are marked with an asterisk. PFS, progression-free survival.
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In conclusion, our study results suggest that patients 
with advanced LPA, formerly advanced BAC, may benefit 
from platinum-based doublet chemotherapy after EGFR-TKI 
failure. In addition, platinum-taxane doublets or pemetrexed 
monotherapy as opposed to platinum-gemcitabine regimens 
appeared to be more promising candidates to be investigated 
in future trials. Lastly, the results of the phase II SWOG 
0526 and IFCT-0504 trials are likely to be instrumental in 
improving our understanding of the clinical and biological 
predictors for paclitaxel-carboplatin doublet and pemetrexed 
activities in advanced LPA, thus facilitating the design of 
future clinical trials.
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